Table 1.
Baseline Patients’ Characteristics.
| Variable | Overall population n = 67, No. (%) |
TLS+ population n = 58, No. (%) |
|---|---|---|
| Age, years | 68 (42–90) | 68 (42–90) |
| Sex | ||
| Male | 37 (55%) | 28 (48%) |
| Female | 30 (45%) | 30 (52%) |
| Tumor location | ||
| Cecum, Ascending colon | 19 (28%) | 18 (31%) |
| Transverse colon | 7 (10%) | 7 (12%) |
| Descending colon | 4 (6%) | 4 (7%) |
| Sigmoid colon | 16 (24%) | 12 (21%) |
| Rectum | 21 (31%) | 17 (29%) |
| Pathologic tumor status | ||
| T2 | 5 (7%) | 4 (7%) |
| T3 | 51 (76%) | 44(76%) |
| T4 | 11 (16%) | 10 (17%) |
| Pathologic node status | ||
| N0 | 22 (33%) | 21 (36%) |
| N1 | 33 (49%) | 29 (50%) |
| N2 | 12 (18%) | 8 (14%) |
| Stage | ||
| II | 22 (33%) | 21 (36%) |
| III | 45 (67%) | 37 (67%) |
| MMR deficiency (dMMR) | 6 (9%) | 6 (10%) |
| Immunoscore | ||
| Low (0-25%) | 53 (79%) | 45 (78%) |
| Intermediate (25-70%) | 13 (19%) | 12 (21%) |
| High (70-100%) | 1 (1.5%) | 1 (1.7%) |
| Adjuvant chemotherapy Yes | 40 (60%) | 34 (59%) |
| Relapse within 2 years | 13 (19%) | 11 (19%) |
| Relapse free survival* median (95% CI) | 9.8 months (6.2–13.5) |
9.8 months (5.7–19.1) |
*estimated from above patients experienced disease relapse
TLS; tertiary lymphoid structure, MMR; mismatch repair, CI; confidence interval